Leading Stem Cell Expert: Stem Cells 101 - The Future of Medicine w/ Robert Hariri | EP #147
Summary
Hariri’s core thesis is that aging depletes the body’s repair inventory: bone-marrow stem cells fall from roughly 1 in 20,000–30,000 cells in an eight-week-old to 1 in 20–30 million at age 80, a 1,000-fold decline. Stem cells are the body’s “regenerative engine,” retaining a readable genome and the versatility to rebuild tissue according to local signals. The therapeutic ambition is therefore supplementation, not passive acceptance of declining repair capacity.
The United States’ bottleneck is regulatory approval, not an absence of international demand or decades of cell-transplant experience. Hariri calls the US “behind the times,” argues that unengineered cell therapy is intrinsically safe, and says its long record lacks a safety signal that should outweigh potential value. Yet he endorses rigorous GMP manufacturing and warns that domestic “mom-and-pop shops” operate in a gray zone; his proposed unlock is provisional approval with real-world data collection, especially for otherwise fatal diseases such as ALS.
Placenta-derived cells are Hariri’s preferred raw material because the organ is young, abundant, normally discarded, and—he argues—naturally immune-tolerant. A fetus and placenta are only a 50/50 genetic match to the mother, while surrogate pregnancies demonstrate tolerance without a genetic match; this underpins his phrase “nature’s universal donor cells.” Celularity, ticker CELU, is building an off-the-shelf platform around placental cells and tissues, while LifebankUSA banks newborn material for potential future repair, immune engineering, and organ manufacture.
The clinical signal presented is compelling but remains divided between anecdotes and evidence standards. Hariri describes Tony Robbins as having a life-changing response after newborn-cell treatment; Hariri and Diamandis separately report substantial orthopedic improvements in their own cases after placental-cell or exosome treatment. Diamandis explicitly calls his same-surgeon, two-shoulder comparison “subjective.” Hariri argues trials are judged with “20th century methodology” despite cell therapy being “a 21st century technology,” while long follow-up, repeat dosing, and combination regimens are too expensive for the development-stage biotechs doing most of the work.
Exosomes offer a cell-free extension of the same regenerative platform. Hariri describes them as membrane-wrapped packets of signaling molecules, growth factors, and microRNAs that fuse with recipient cells to deliver anti-inflammatory or pro-regenerative instructions—a “special delivery package.” That mechanism supports opportunities across orthopedics, skin, hair, and inflammation, but the episode offers personal outcomes rather than controlled efficacy data.
Skeletal muscle emerges as a major longevity market rather than merely a fitness category. Hariri calls it the “forgotten organ”: about 50% of wet body mass, a producer of signals affecting the brain and immune system, and a reservoir for stem and immune cells. He cites a Karolinska Institute study following 9,000 men for 25 years in which lean muscle and strength predicted resistance to death from cancer or heart disease better than BMI; Diamandis’s direct investor call is, “Any company that increases muscle mass is a company I want to look at investing in.”
The longer-duration platform thesis is replacement biology: preserve cells, detect failure early, and eventually remanufacture damaged parts. Diamandis compares banked newborn cells to being born with “an extra set of kidneys, extra set of lungs and an extra heart,” while Hariri’s earlier work stripped cells from organs to leave a reusable three-dimensional matrix that new stem cells could repopulate. Celularity was spun out of Celgene’s cellular-medicine division, which Diamandis says reached about $120 billion in market capitalization at its peak. Celularity’s nearer-term products—placental tissue for wounds, orthopedics, and ophthalmology, plus cellular programs—sit on the path toward that broader vision.
Deep dive
1. Regulation, not biology, keeps US patients traveling
Diamandis opens with the market anomaly: Americans can seek stem cells in Panama, Costa Rica, Mexico, Antigua, or Bali, but cannot obtain comparable FDA-approved treatments at home. Hariri traces that gap to the FDA’s conservative process for proving safety and efficacy, calling the United States “behind the times.”
Hariri’s safety claim is categorical but scoped: he personally believes cell therapy “in almost any iteration in the unengineered form is intrinsically safe.” Bone-marrow transplantation is already stem-cell transplantation, treatments have occurred for decades, and he says no long-term safety signal has emerged that should create broad concern.
His policy prescription requires “a little bit of courage”: jurisdictions in Asia, Eastern Europe, and the Middle East are more willing to provide abbreviated approval pathways, while US regulators should weigh therapeutic potential against what he calls the “nominal risk” of remaining uncertainty.
2. Stem cells are the body’s renewable construction stock
Hariri starts at conception: one totipotent cell ultimately produces every specialized cell across a body of roughly 40 trillion cells. Differentiation creates brain, liver, bone, blood, and other tissue, while a residual stem-cell population “reserves the right” either to specialize or copy itself.
The contractor analogy carries the mechanism: “Just like you renovate your home to keep it in perfect operating condition, it’s best to renovate with the original materials.” Nature leaves stem cells inside each organ like spare tiles and plumbing supplies, forming a “natural repair kit” that responds to injury and routine turnover.
These cells do not choose a fate arbitrarily. Hariri says each tissue’s structural matrix supplies chemical location signals—like a shopping-mall map saying “you are here”—so a versatile cell reaching the liver becomes an appropriate liver-associated cell rather than mistakenly becoming a neuron.
At the software layer, specialized cells silence genome segments they no longer need, while stem cells retain what Hariri calls the “fully transcribable genome.” His signature framing is a “perfect uncorrupted reboot disk”: a stem cell can reread biological software after mutation, exhaustion, or chemical damage compromises mature cells.
3. Aging is a thousandfold loss of repair capacity
In bone marrow, Hariri says roughly 1 in every 20,000–30,000 cells is a stem cell in an eight-week-old; by age 80, the ratio is about 1 in 20–30 million. That exponential, approximately 1,000-fold decline makes repair cells harder to recruit precisely when accumulated damage raises demand.
The mansion metaphor extends from missing materials to missing labor: repair workers disappear and their instructions blur, leaving the structure progressively less capable of returning to its original condition. Stem-cell exhaustion is therefore presented as both a hallmark of aging and a causal constraint on regeneration.
Diamandis frames supplementation as the actionable alternative to accepting the post-peak decline in muscle, immunity, hormones, and repair capacity. Hariri agrees that augmenting the reservoir should be beneficial in principle, though the later discussion makes clear that approved protocols and definitive outcome data remain the constraint.
Hariri’s longevity-specific data point is an early experiment: newborn rats had placental cells collected, processed, stored, and returned as the animals aged; he says treated animals lived 40% longer than untreated animals. The episode provides no design details, so the result remains a directional rationale rather than a clinical forecast.
4. The placenta is both a biological factory and a bankable asset
Hariri’s interest began during his daughter’s first-trimester ultrasound: the embryo was “peanut size,” yet the placenta was already large. That observation led him to question the idea that it was merely a vascular connection and instead see it as a “3D printer” and supply depot helping manufacture the baby.
At delivery, cord blood contains hematopoietic stem cells, but Hariri and Diamandis argue the placenta offers a much broader collection of cells and tissue structures. Ordinarily, the cord and placenta enter biohazard waste; cryopreservation instead puts their cells into “suspended animation” for possible future use.
Diamandis calls newborn placental banking a “moral obligation” for parents. Hariri’s narrower rationale is option value: banked young cells could eventually support genome editing, engineered immune cells, autoimmune repair, regenerative treatments, or tissue manufacture as those technologies mature.
Scale strengthens the platform thesis. Hariri contrasts the handful of cells obtainable from an embryo with the “billion cells easily, multi-billion cells” obtainable from one placenta, which is collected after birth from material otherwise discarded.
5. Placental cells sidestep both matching and the original ethics fight
Autologous therapy uses a patient’s own cells, sourced from blood, bone marrow, adipose tissue, or another harvested tissue. Allogeneic therapy uses somebody else’s cells and supports an off-the-shelf product, but ordinarily requires managing immune conflict between donor and recipient.
Hariri argues placental cells are “nature’s universal donor cells.” A fetus and its placenta carry half their DNA from the father yet coexist with the mother; in a surrogate pregnancy, neither is genetically related to the surrogate. In his account, mammalian reproduction itself demonstrates the tissue’s unusual immune tolerance.
Induced pluripotent stem cells offer another route by reprogramming mature skin or other cells with Yamanaka’s method. Hariri admires the technology but argues that switching pluripotency back on does not erase every aspect of cellular age: mitochondria, membranes, and other structures remain old, making newborn placental cells his preferred starting canvas.
The original stem-cell controversy centered on destroying unused IVF embryos or deriving cells from fetal material after abortion. Hariri’s answer is that full-term placenta is “pro-life and pro-choice”: it is ethically less contentious, economically abundant, and normally discarded after a healthy birth.
6. Anecdotes are strong enough to create demand, not settle efficacy
Tony Robbins is the flagship orthopedic example: after severe shoulder, hip, and back injuries, he faced prosthetic-replacement surgery or an attempt to increase regeneration. Hariri says augmenting Robbins’s limited adult repair pool with newborn cells produced the “life-changing response” described in their book.
Diamandis offers a within-person comparison: the same surgeon performed the exact same bone-spur and rotator-cuff operation on his two shoulders roughly 10 years apart. The older shoulder received two exosome injections yet recovered faster with less pain; he immediately concedes, “This is subjective, but it was like, wow, that was different.”
Hariri reports similar pain and function improvements after placental cells in one damaged shoulder and exosomes in the other. He says the treatment turned off processes associated with longer-term dysfunction, including scarring and changes to bone and cartilage. His conclusion is “proof in practice,” while Diamandis’s question about clinical trials preserves the unresolved distinction between personal experience and controlled evidence.
An exosome, in Hariri’s definition, is a membrane-wrapped extracellular vesicle containing signaling molecules, growth factors, and microRNAs. It fuses with a recipient cell and delivers anti-inflammatory or pro-regenerative information—a “special delivery package”—without administering the parent cell itself.
7. Cell-therapy trials collide with time, cost, and outdated endpoints
Hariri says many trials have been conducted, including in heart failure after myocardial infarction, but disputes how some results were analyzed. His central criticism: “We’re using 20th century methodology to evaluate clinical trials in cell therapy—that’s a 21st century technology,” so endpoints and observation periods may miss gradual repair.
Longer lenses mean following outcomes for six months, one year, or two years, potentially across repeated treatments. That becomes cost-prohibitive because the field is populated largely by development-stage biotechs rather than large pharmaceutical companies, leaving approval odds constrained by how much capital each company can raise.
His proposed compromise is rigorous GMP manufacturing, release testing, and evidence of acute and longer-term safety, followed by provisional clinical use and structured data collection. For ALS, where he says “nothing works” and death is expected, he sees little downside to trying products that clear that safety threshold.
Hariri also suspects cells may deliver their best return alongside conventional drugs or other treatments, a combination the current system does not readily test. Real-world deployment could generate the 10,000-patient datasets AI needs, rather than isolated cohorts of 10 or 100; he believes Bobby Kennedy may support a more inclusive development model.
8. Muscle is the regenerative market hiding in plain sight
Hariri calls skeletal muscle the “forgotten organ”: it represents about 50% of an average person’s wet body mass and produces an array of signals that influence the brain, immune system, and other tissues. Its low-pressure vascular network also serves as a waiting reservoir for stem and immune cells.
That biology drove his early interest in blocking myostatin, a protein that limits lean-muscle growth, through nutritional and pharmaceutical approaches. The goal is preserved muscle quality, growth, strength, mobility, and signaling across the body.
Hariri cites a Karolinska Institute study that followed 9,000 men for 25 years. Men who maintained lean muscle and strength—even when BMI classified them as obese—showed greater resistance to death from cancer or heart disease than indicated by BMI, weight, or the other metabolic markers he names.
9. The endgame joins early detection, organ renewal, and Celularity
Hariri defines meaningful longevity as four preserved capacities: “high-performance mobility,” cognition, immunity, and “youthful aesthetics.” Fountain Life’s first task is eliminating premature death through imaging and diagnostics that find cardiovascular threats and cancers while they remain actionable. Diamandis says its workup uploads about 200 gigabytes from full-body and brain MRI, DEXA, coronary CT with an AI overlay, low-dose lung CT, biomarkers, genomics, metabolomics, microbiome data, and more.
Diamandis’s example is Sam Nazarian, whose access to the best physicians had not revealed two brain aneurysms; Fountain Life imaging identified them, and surgery followed within a week. Hariri says aneurysms are relatively easy to spot when the imaging study is available and that early detection gives patients more treatment options; he cites subclinical kidney cancer as another example.
The organ-replacement analogy makes cell banking tangible: “If your baby was born with an extra set of kidneys, extra set of lungs and an extra heart, would you throw them out at birth?” Hariri says he was the first to remove all living cells from a solid organ; he began with placenta and also worked with hearts, leaving three-dimensional matrices whose vessels, valves, and structural proteins could be repopulated with stem cells.
That patent became, in Hariri’s telling, a roadmap for work now pursued by Martine Rothblatt and Dean Kamen: versatile cells placed into a preserved matrix read its positional signals and differentiate appropriately. Celularity’s nearer-term platform, ticker CELU, separates placental tissue into wound-healing, orthopedic, and ophthalmic products, while its cellular side produces immune-cell, stem-cell, and other therapeutic candidates. Diamandis says Celularity was spun out of Celgene’s cellular-medicine division, which reached about $120 billion in market capitalization at its peak.